7 news items
BioLineRx Announces Clinical Trial Agreement with St. Jude Children's Research Hospital, Inc. to Evaluate Motixafortide for CD34+ Hematopoietic Stem Cell (HSC) Mobilization For Gene Therapy Applications in Sickle Cell Disease (SCD)
BLRX
30 May 24
expectations constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995
BioLineRx Reports First Quarter 2024 Financial Results and Recent Corporate and Portfolio Updates
BLRX
28 May 24
" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include words such as "anticipates
BioLineRx Announces Abstract on Pilot Study Data from Phase 2 Combination Clinical Trial Evaluating Motixafortide in First-Line Pancreatic Cancer (PDAC) at American Society of Clinical Oncology (ASCO) 2024 Annual Meeting
BLRX
24 May 24
statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include words such as "anticipates
BioLineRx Announces Receipt of Nasdaq Minimum Bid Price Notification
BLRX
17 May 24
future expectations constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995
BioLineRx Announces Poster Presentation on Economic Model Data for APHEXDA® (motixafortide) as part of CD34+ Hematopoietic Stem Cell Mobilization in Patients with Multiple Myeloma at ISPOR 2024
BLRX
6 May 24
"forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include words
vhqrm26flo2faurjat64d9zyzal4rh
BLRX
17 Apr 24
concerning BioLineRx's future expectations constitute "forward-looking statements" within the meaning of the Private Securities Litigation
j3ldmd9ky1 lehs21ny54l9hqo8qv
BLRX
4 Mar 24
expectations constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995
- Prev
- 1
- Next